Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X)

Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X)

Objectives To investigate the long-term safety and efficacy of otilimab, an antigranulocyte-macrophage colony-stimulating factor monoclonal antibody, for patients with rheumatoid arthritis (RA).Methods ContRAst X (NCT04333147) was a phase 3, multicentre, long-term extension trial. Patients with RA a...

Full description

Saved in:
Bibliographic Details
Main Authors: Tsutomu Takeuchi, Iain B McInnes, Peter C Taylor, Roy M Fleischmann, Vibeke Strand, Michael E Weinblatt, David Brooks, Tatsuya Atsumi, Paula Curtis, Marguerite Bracher, Anubha Gupta, Didier Saurigny, Celia Shelton, Millie Wang, Reena Wang, Rina Nijhawan, Ciara O'Shea, Kirsty Rayner
Format: Article
Language:English
Published: BMJ Publishing Group 2025-03-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/15/3/e088869.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopen.bmj.com/content/15/3/e088869.full

Similar Items